Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: A pilot study
Autore:
Sands, BE; Tremaine, WJ; Sandborn, WJ; Rutgeerts, PJ; Hanauer, SB; Mayer, L; Targan, SR; Podolsky, DK;
Indirizzi:
Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA Massachusetts Gen Hosp Boston MA USA 02114 nal Unit, Boston, MA 02114 USA Massachusetts Gen Hosp, Ctr Study Inflammatory Bowel Dis, Boston, MA 02114USA Massachusetts Gen Hosp Boston MA USA 02114 Bowel Dis, Boston, MA 02114USA Mayo Clin, Rochester, MN USA Mayo Clin Rochester MN USAMayo Clin, Rochester, MN USA Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium Univ Hosp Gasthuisberg Louvain Belgium B-3000 g, B-3000 Louvain, Belgium Univ Chicago, Chicago, IL 60637 USA Univ Chicago Chicago IL USA 60637Univ Chicago, Chicago, IL 60637 USA Mt Sinai Hosp, New York, NY 10029 USA Mt Sinai Hosp New York NY USA 10029Mt Sinai Hosp, New York, NY 10029 USA Cedars Sinai Hosp, Los Angeles, CA USA Cedars Sinai Hosp Los Angeles CA USA ars Sinai Hosp, Los Angeles, CA USA
Titolo Testata:
INFLAMMATORY BOWEL DISEASES
fascicolo: 2, volume: 7, anno: 2001,
pagine: 83 - 88
SICI:
1078-0998(200105)7:2<83:IITTOS>2.0.ZU;2-M
Fonte:
ISI
Lingua:
ENG
Soggetto:
TUMOR-NECROSIS-FACTOR; INFLAMMATORY BOWEL-DISEASE; MONOCLONAL-ANTIBODY CA2; CROHNS-DISEASE; FACTOR-ALPHA; INTESTINAL BIOPSIES; TNF-ALPHA; CYCLOSPORINE; CYTOKINES; THERAPY;
Keywords:
infliximab; monoclonal antibody; steroid-refractory; tumor necrosis factor alpha; ulcerative colitis;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
22
Recensione:
Indirizzi per estratti:
Indirizzo: Sands, BE Massachusetts Gen Hosp, Gastrointestinal Unit, 55 Fruit St,GRJ 825, Boston, MA 02114 USA Massachusetts Gen Hosp 55 Fruit St,GRJ 825 Boston MA USA 02114 A
Citazione:
B.E. Sands et al., "Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: A pilot study", INFLAMM B D, 7(2), 2001, pp. 83-88

Abstract

We report the experience of 11 patients (of 60 planned patients) enrolled in a double-blind, placebo-controlled clinical trial of infliximab in patients with severe, active steroid-refractory ulcerative colitis. The study was terminated prematurely because of slow enrollment. Patients having activedisease for at least 2 weeks and receiving at least 5 days of intravenous corticosteroids were eligible to receive a single intravenous infusion of infliximab at 5, 10, or 20 mg/kg body weight. The primary endpoint used in this study was treatment failure at 2 weeks after infusion. Treatment failure was defined as 1) unachieved clinical response as defined by a modified Truelove and Witts severity score, 2) increase in corticosteroid dosage, 3) addition of immunosuppressants, 4) colectomy, or 5) death. Safety evaluations included physical examination, clinical chemistry and hematology laboratory tests, and occurrence of adverse experiences. Four of 8 patients (50%) who received infliximab were considered treatment successes at 2 weeks. compared with none of 3 patients who received placebo. Improvement in erythrocyte sedimentation rates and serum concentrations of C-reactive protein and interleukin-6 correlated with the clinical response observed in patients receiving infliximab. Infusion with infliximab produced no significant adverse events. Infliximab was well tolerated and may provide clinical benefit fur some patients with steroid-refractory ulcerative colitis.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 09/04/20 alle ore 19:18:30